$MNKD

Binder Steven B. sold $213K of MNKD

Binder Steven B. sold 52,485 shares of MANNKIND CORP (MNKD) at $4.06 ($0.21M total) on 2026-07-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Binder Steven B.
Published Jul 17, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 5:50 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MNKD
Neutral
medium confidence
Mentioned
$MNKD
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MNKDNeutralLow
01

Why it matters

Traders may monitor insider activity for sentiment, but this specific disclosure lacks any new company fundamentals, guidance, or regulatory/clinical catalysts.

02

Market read

A routine director sale is disclosed; absent other catalysts, it is unlikely to drive a durable repricing.

03

What to watch

The article does not state whether other insiders sold/bought, nor does it provide context on total insider holdings changes beyond the post-transaction share count.

Relevance 3/10Novelty 3/10Timing: filed 2026-07-17, after-hours/late session disclosure window

Background

The article is an SEC Form 4 insider transaction disclosure for MannKind Corp, reported as an open-market sale by a director under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$MNKDNeutralMedium confidence
Context

MannKind director Steven B. Binder sold 52,485 shares in an open-market transaction for about $213,089 under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and typically fades unless paired with other news.

Evidence & confidence

The filing is a routine Form 4 open-market sale by a director, explicitly under a pre-arranged 10b5-1 plan, with no accompanying operational or financial guidance changes in the text.

Market effects

No sector read-through is provided; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.

Key entities

  • MannKind Corp

    US-listed company (MNKD) whose director insider sale is disclosed on Form 4.

  • Steven B. Binder

    Director who sold 52,485 shares at $4.0600/share on 2026-07-17 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MNKDMedAI 8/10

MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth

MannKind (MNKD) advances inhaled IPF drug to global Phase 2, with potential human testing by year-end. CEO Castagna highlights FUROSCIX's strong adoption, shifting sales focus to nephrology. Company reports sufficient cash for growth, aiming for profitability next year. Vicore Pharma's Phase 2b study for IPF treatment expected to report results in summer 2025.

$MNKDMedAI 8/10

A heart-failure injector delivers a full dose in under 10 seconds. Urine output was similar to treatment into a vein.

MannKind (MNKD) presented clinical data at HFSA 2026 showing Furoscix ReadyFlow's comparable urine output to IV furosemide. The autoinjector delivers an 80 mg/mL dose in under 10 seconds, with 91.3% and 92.7% bioavailability in thigh and upper-arm injections, respectively. ReadyFlow received FDA approval in July 2026 for fluid overload treatment in heart failure or CKD patients.